Acute and Subacute Endocarditis with CC DRG Reimbursement

DRG 289 addresses acute and subacute infective endocarditis with a Complication or Comorbidity, covering admissions that require intensive medical management and possibly cardiac surgery. It matters for inpatient reimbursement because documented complications and comorbid conditions determine Diagnosis-Related Group assignment and influence Medicare payment levels.

DRG 289 Overview

DRG 289 covers hospital admissions for acute and subacute infective endocarditis when a Complication or Comorbidity is present, encompassing medical and procedural management such as prolonged intravenous antimicrobial therapy and potential surgical intervention. This Diagnosis-Related Group is clinically significant because case complexity and comorbid conditions drive resource use, length of stay, and Medicare reimbursement. Accurate coding of underlying infection, causative organism, and associated Complication or Comorbidity affects payment assignment and hospital revenue. Understanding the clinical scope supports correct Diagnosis-Related Group assignment for inpatient claims.

DRG 289 Overview

Acute antimicrobial strategy and duration trials: randomized or pragmatic studies comparing different intravenous antibiotic regimens, shorter versus standard therapy durations, or early switch-to-oral protocols for hospitalized adults with acute and subacute bacterial endocarditis complicated by coexisting conditions (eg, prosthetic valves, Staphylococcus aureus bacteremia). These studies enroll patients during the index hospital stay, often stratified by organism, valve type (native vs prosthetic), and presence of complications such as embolic events or heart failure; they address whether shorter or modified inpatient treatment pathways maintain cure rates while reducing length of stay and central line–related complications. Results are directly relevant to inpatient providers and payers because they inform safe opportunities to reduce hospital days, antibiotic costs, and device-associated adverse events while preserving clinical outcomes for this high-cost DRG.
Comparative effectiveness and procedural timing studies (medical vs surgical management): observational cohorts or randomized designs examining outcomes of early valve surgery versus delayed or medical-only management in patients with acute/subacute infective endocarditis who have heart failure, large vegetations, or persistent bacteremia. These studies target the perihospital decision-making window, comparing short-term mortality, readmissions, complication rates, and resource use across patient subgroups (eg, prosthetic valve involvement, intracardiac devices, renal dysfunction). Findings guide clinicians and hospital administrators on which patients benefit from expedited surgical intervention and help payers anticipate operative resource needs and downstream costs associated with different management strategies within this DRG.
Post-discharge outcomes, readmission prevention, and transitional care interventions: prospective cohort studies or care-pathway trials testing structured discharge programs, outpatient parenteral antimicrobial therapy (OPAT) models, telehealth follow-up, and multidisciplinary endocarditis teams to reduce 30- and 90-day readmissions and monitor late complications (eg, recurrent infection, valve dysfunction, adverse drug events). These trials enroll patients at discharge or shortly thereafter, frequently including those with social complexities, renal impairment, or substance use disorders who are at higher risk for readmission and treatment failure. Results inform hospital discharge planning, case management, and payer policies by identifying interventions that improve continuity of care, lower readmission rates, and optimize total episode-of-care costs for this DRG.

Acute antimicrobial strategy and duration trials: randomized or pragmatic studies comparing different intravenous antibiotic regimens, shorter versus standard therapy durations, or early switch-to-oral protocols for hospitalized adults with acute and subacute bacterial endocarditis complicated by coexisting conditions (eg, prosthetic valves, Staphylococcus aureus bacteremia). These studies enroll patients during the index hospital stay, often stratified by organism, valve type (native vs prosthetic), and presence of complications such as embolic events or heart failure; they address whether shorter or modified inpatient treatment pathways maintain cure rates while reducing length of stay and central line–related complications. Results are directly relevant to inpatient providers and payers because they inform safe opportunities to reduce hospital days, antibiotic costs, and device-associated adverse events while preserving clinical outcomes for this high-cost DRG.
Comparative effectiveness and procedural timing studies (medical vs surgical management): observational cohorts or randomized designs examining outcomes of early valve surgery versus delayed or medical-only management in patients with acute/subacute infective endocarditis who have heart failure, large vegetations, or persistent bacteremia. These studies target the perihospital decision-making window, comparing short-term mortality, readmissions, complication rates, and resource use across patient subgroups (eg, prosthetic valve involvement, intracardiac devices, renal dysfunction). Findings guide clinicians and hospital administrators on which patients benefit from expedited surgical intervention and help payers anticipate operative resource needs and downstream costs associated with different management strategies within this DRG.
Post-discharge outcomes, readmission prevention, and transitional care interventions: prospective cohort studies or care-pathway trials testing structured discharge programs, outpatient parenteral antimicrobial therapy (OPAT) models, telehealth follow-up, and multidisciplinary endocarditis teams to reduce 30- and 90-day readmissions and monitor late complications (eg, recurrent infection, valve dysfunction, adverse drug events). These trials enroll patients at discharge or shortly thereafter, frequently including those with social complexities, renal impairment, or substance use disorders who are at higher risk for readmission and treatment failure. Results inform hospital discharge planning, case management, and payer policies by identifying interventions that improve continuity of care, lower readmission rates, and optimize total episode-of-care costs for this DRG.

OpenPayer

Acute and Subacute Endocarditis with CC: Inpatient Reimbursement Overview

Sign up for drg 289 policy alerts

DRG 289 Overview

OpenPayer

Acute and Subacute Endocarditis with CC: Inpatient Reimbursement Overview

Sign up for drg 289 policy alerts

DRG 289 Overview

Clinical Trials

Related Codes

References

Clinical Trials

Related Codes

References